- The trend backdrop is active with a 14-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
RUBICON
NSI
Week ended 07 Aug 2026
Weekly Investor Report
RUBICON RESEARCH LIMITED · Healthcare · Drug Manufacturers - General
Latest close
1,553 INR
4.3%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 52.6% above the Trend Line and sits at 96.6% of its 52-week range. The latest completed week returned 4.3%, after a 8.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 55/100. Near-term considerations: price is close to its 52-week high.
Setup score
68
out of 100
Latest Close
1,553 INR
7 Aug 2026
1W Return
4.3%
latest completed week
4W Return
8.6%
short-term follow-through
12W Return
61.6%
quarterly tape
Trend Breadth
32.6%
14 of 43 weeks active
Volume Ratio
1.0x
vs 13-week average
- 5 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
4.3%
Latest completed week; four-week move 8.6%.
Indicator stack
63/75
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Positive 66.55%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
55/100
35 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 52.6% above the Trend Line and sits at 96.6% of its 52-week range. The latest completed week returned 4.3%, after a 8.6% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9512-week average 0.90
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.95Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers55 reversal markers
No recent accumulation markers. 5 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 8.6% over four weeks, 61.6% over 12 weeks, and - over one year. The current trend has remained active for 14 consecutive weeks.
Performance by holding period
Active trend streak14 weeks
Active weeks in one year14
Trend breadth32.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.46Latest activity-pressure read.
Pressure change-17.4%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 77%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value2/100Relative valuation strength. Underlying universe rank 99; rank 1 is best.
Quality74/100Profitability and accounting quality. Underlying universe rank 27; rank 1 is best.
Momentum40/100Medium-term price momentum. Underlying universe rank 61; rank 1 is best.
Growth81/100Revenue and earnings growth. Underlying universe rank 20; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework20/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 114.5x Price divided by trailing earnings.
- Price / sales
- 15.4x Market value relative to trailing revenue.
- EV / EBITDA
- 68.5x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 67.7% Gross profit retained from each unit of revenue.
- Operating margin
- 19.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -1.5% Free cash flow generated from revenue.
- Return on invested capital
- 17.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 36.6% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.1% Cash dividends relative to market value.
- Buyback yield
- -1.9% Net share repurchases relative to market value.
- Shareholder yield
- -1.8% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment55/100
Weighted news tone is neutral across 35 relevant articles.
9 positive · 26 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-2.2%Distance below the 52-week high.
13-week volatility6.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher18 of 268 weeks finished lower.
Best week+19.6%Week of 5 Jun.
Worst week-7.8%Week of 3 Jul.
Latest week+4.3%Week of 7 Aug.
Shape of recent returns
Strong gains11
Modest gains7
Flat weeks0
Modest losses7
Sharp losses1
Recent vol6.3%13-week weekly-return volatility.
Base vol5.6%52-week weekly-return volatility.
Up/down split27/15Count of positive and negative weeks in the 52-week window.
Average skew5.3% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank18 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - General
4-week rank2 / 11
Group average2.2%
Trend breadth72.7%
Trend72.7%active weekly trend signals
MD81.8%positive activity pressure
RS72.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape64/100
Trend, activity pressure, participation, and risk combine to a 64/100 tape read.
Indicator analysis64/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.95; 5 reversal markers Next-Week ExpectancyPositive 66.55%Next-week expectancy is positive with a 66.55% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors31/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 85 SVQF20/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1262.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment55/100Weighted news tone is neutral across 35 relevant articles.
Rubicon Research Limited Submits Business Responsibility and Sustainability Report for FY 2025-26 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,553 INR | 4.3% | 1,018 INR | 905.5 INR | 1.46 | - | 804.3K | On |
| 31 Jul 2026 | 1,490 INR | -1.9% | 987.5 INR | 890.1 INR | 1.51 | - | 789.5K | On |
| 24 Jul 2026 | 1,519 INR | 5.6% | 959.9 INR | 875.5 INR | 1.46 | - | 1.7M | On |
| 17 Jul 2026 | 1,438 INR | 0.6% | 932.0 INR | 859.4 INR | 1.56 | - | 1.5M | On |
| 10 Jul 2026 | 1,430 INR | 9.5% | 905.9 INR | 844.6 INR | 1.77 | - | 1.1M | On |
| 3 Jul 2026 | 1,306 INR | -7.8% | 879.5 INR | 829.2 INR | 2.01 | - | 326.2K | On |
| 26 Jun 2026 | 1,417 INR | 4.0% | 857.1 INR | 816.3 INR | 2.37 | - | 0 | On |
| 19 Jun 2026 | 1,362 INR | 5.1% | 831.8 INR | 799.6 INR | 2.37 | - | 334.8K | On |
| 12 Jun 2026 | 1,296 INR | 7.7% | 809.0 INR | 783.5 INR | 2.25 | - | 664.7K | On |
| 5 Jun 2026 | 1,202 INR | 19.6% | 789.6 INR | 768.5 INR | 2.19 | - | 637.7K | On |
| 29 May 2026 | 1,006 INR | 5.9% | 770.4 INR | 755.3 INR | 2.24 | - | 597.3K | On |
| 22 May 2026 | 949.8 INR | -1.2% | 757.5 INR | 747.5 INR | 2.37 | - | 836.6K | On |
| 15 May 2026 | 961.0 INR | 0.5% | 745.1 INR | 741.0 INR | 2.57 | - | 670.2K | On |
| 8 May 2026 | 955.8 INR | -1.5% | 733.7 INR | 733.7 INR | 2.61 | - | 1.1M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.